866-997-4948(US-Canada Toll Free)

Metastatic Renal Cell Cancer Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Cancer

No. of Pages : 51 Pages


Global Markets Directs, \'Metastatic Renal Cell Cancer Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Renal Cell Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Cancer. 

Metastatic Renal Cell Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Renal Cell Cancer.
  • A review of the Metastatic Renal Cell Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Renal Cell Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Renal Cell Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Metastatic Renal Cell Cancer 7
Metastatic Renal Cell Cancer Therapeutics under Development by Companies 9
Metastatic Renal Cell Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Metastatic Renal Cell Cancer Therapeutics Products under Development by Companies 14
Metastatic Renal Cell Cancer Therapeutics Products under Investigation by Universities/Institutes 15
Companies Involved in Metastatic Renal Cell Cancer Therapeutics Development 16
Novartis AG 16
Argos Therapeutics, Inc. 17
Syndax Pharmaceuticals, Inc. 18
Metastatic Renal Cell Cancer Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
everolimus - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ispinesib mesylate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AGS-003 + Sutent - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
sunitinib malate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes + ALVAC ESO-1 Vaccine + Cyclophosphamide + Fludarabine + Aldesleukin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 33
Zanolimumab + Aldesleukin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Anti-NY ESO-1 TCR-Gene Engineered Autologous Lymphocytes + Aldesleukin + Cyclophosphamide + Fludarabine Phosphate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 36
Denileukin Diftitox + Aldesleukin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Proleukin + Entinostat - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Metastatic Renal Cell Cancer Therapeutics Drug Profile Updates 39
Metastatic Renal Cell Cancer Therapeutics Discontinued Products 45
Metastatic Renal Cell Cancer Therapeutics - Dormant Products 46
Metastatic Renal Cell Cancer Product Development Milestones 47
Featured News & Press Releases 47
Sep 20, 2012: Aveo Oncology To Present New Clinical Data On Tivozanib At ESMO 2012 Congress 47
Jun 01, 2012: Bionomics To Present Clinical Trial Data Of BNC105 At ASCO Meeting 47
May 29, 2009: Bayer Schering Pharma To Present Data on Oncology Development Compound BAY 73-4506 48

Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Table


Number of Products Under Development for Metastatic Renal Cell Cancer, H2 2012 7
Products under Development for Metastatic Renal Cell Cancer Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Novartis AG, H2 2012 16
Argos Therapeutics, Inc., H2 2012 17
Syndax Pharmaceuticals, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Metastatic Renal Cell Cancer Therapeutics Drug Profile Updates 39
Metastatic Renal Cell Cancer Therapeutics Discontinued Products 45
Metastatic Renal Cell Cancer Therapeutics Dormant Products 46

List of Chart


Number of Products under Development for Metastatic Renal Cell Cancer, H2 2012 7
Products under Development for Metastatic Renal Cell Cancer Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *